Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Aethlon Medical ( (AEMD) ).
In its recent financial release, Aethlon Medical reported a significant milestone in its oncology trials in Australia, announcing the first patient treated with the Hemopurifier for solid tumors not responding to anti-PD-1 antibodies on January 29, 2025. The company has also implemented strategic cost-cutting measures, reducing operating expenses by 50% from the previous year, and made protocol amendments to accelerate trial timelines and improve patient enrollment. These developments are crucial for enhancing the company’s clinical program efficiency and potentially improving therapeutic responses in future oncology efficacy trials.
More about Aethlon Medical
Aethlon Medical, Inc. is a medical therapeutic company specializing in developing treatments for cancer and life-threatening infectious diseases. The company’s primary focus is on oncology trials, particularly the Hemopurifier, designed to treat cancer patients unresponsive to certain therapies.
YTD Price Performance: -14.88%
Average Trading Volume: 3,395,733
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.49M
See more insights into AEMD stock on TipRanks’ Stock Analysis page.
